About
I love histopathology and focus in IHC/ISH and digital imaging.
Activity
-
Aiosyn has partnered with HistoWiz for a pilot study! The collaboration integrates Aiosyn’s NephroPath kidney analysis algorithms into HistoWiz’s…
Aiosyn has partnered with HistoWiz for a pilot study! The collaboration integrates Aiosyn’s NephroPath kidney analysis algorithms into HistoWiz’s…
Liked by Patrick Savickas
-
October is Breast Cancer Awareness Month, and at HistoWiz, we’re committed to advancing breast cancer research through cutting-edge histopathology…
October is Breast Cancer Awareness Month, and at HistoWiz, we’re committed to advancing breast cancer research through cutting-edge histopathology…
Liked by Patrick Savickas
-
WONDERING HOW PATHOLOGISTS ARE USING DIGITAL PATHOLOGY TO ENHANCE THEIR WORK? Join us for Session no 6 of the DPA Grand Rounds where Jeffrey Fine…
WONDERING HOW PATHOLOGISTS ARE USING DIGITAL PATHOLOGY TO ENHANCE THEIR WORK? Join us for Session no 6 of the DPA Grand Rounds where Jeffrey Fine…
Liked by Patrick Savickas
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
Activities and Societies: Umass Road Cycling Team
Honors & Awards
-
John Adams Scholar
-
More activity by Patrick
-
⭐️UPDATE⭐️ ViewsML was highly attended today at National Society for Histotechnology and we were asked to speak again tomorrow! We hope to catch you…
⭐️UPDATE⭐️ ViewsML was highly attended today at National Society for Histotechnology and we were asked to speak again tomorrow! We hope to catch you…
Liked by Patrick Savickas
-
Watch our RNAscope ISH Spatial Multiomic Assay workshop presented by Stacy Star Moskowitz from Novartis and Aman Tyagi from Advanced Cell Diagnostics…
Watch our RNAscope ISH Spatial Multiomic Assay workshop presented by Stacy Star Moskowitz from Novartis and Aman Tyagi from Advanced Cell Diagnostics…
Liked by Patrick Savickas
-
Join us at #SfN24 in Chicago, where we’ll be diving into groundbreaking research on the spatial signature of GPNMB in glioblastoma. Rachel Clary…
Join us at #SfN24 in Chicago, where we’ll be diving into groundbreaking research on the spatial signature of GPNMB in glioblastoma. Rachel Clary…
Liked by Patrick Savickas
-
Great for Doroteya Raykova and Hampus Elofsson to present Navinci Diagnostics assays automated on Leica Biosystems BOND RX at the National Society…
Great for Doroteya Raykova and Hampus Elofsson to present Navinci Diagnostics assays automated on Leica Biosystems BOND RX at the National Society…
Liked by Patrick Savickas
-
Are you in New Orleans for the National Society for Histotechnology 2024 convention? 🎷 We are very excited to be hosting a joint workshop tomorrow…
Are you in New Orleans for the National Society for Histotechnology 2024 convention? 🎷 We are very excited to be hosting a joint workshop tomorrow…
Liked by Patrick Savickas
-
Join us tomorrow morning at the NSH Convention in New Orleans! Patrick J. Savickas and Jack Casey will be presenting “Multiomics: The Best of…
Join us tomorrow morning at the NSH Convention in New Orleans! Patrick J. Savickas and Jack Casey will be presenting “Multiomics: The Best of…
Liked by Patrick Savickas
Other similar profiles
Explore more posts
-
CD Genomics
Empower Your Cancer Research with CD Genomics' Advanced CNV Reference Products Excited to share our latest breakthrough in cancer research! CD Genomics introduces our cutting-edge CNV Reference Products, revolutionizing how laboratories approach cancer diagnostics and treatment development. Here's why you need to explore our offerings: Accurate Replication of CNV Profiles: Our reference mixture mirrors CNV profiles observed in lung, brain, and breast cancers, featuring crucial genes like EGFR, MYCN, MET, ERBB2, FGFR3, and MYC. Achieve precise emulation for robust research and clinical assessments. Cost-Efficiency Redefined: With a single sample encompassing three clinically relevant CNVs, we slash costs associated with specimen collection and sequencing. Develop, optimize, and validate CNV assays without multiple independent samples, maximizing efficiency. Comprehensive Multi-Gene Coverage: Explore CNV profiles across multiple genes simultaneously, broadening horizons in cancer analysis. Our mixtures include pivotal genes associated with various cancer types, empowering comprehensive research and diagnostics. Unwavering Experimental Reproducibility: Gain access to stable and consistent samples with our CNV Reference Mixture. Ensure high reliability and confidence in experimental findings, vital for advancing research and clinical investigations. Advancing (Pre-)Clinical Research: Dive deeper into the intricate relationship between CNV patterns and cancer progression. Our products provide critical insights for more informed decision-making in cancer treatment strategies, driving innovation in healthcare. Applications: From advanced CNV assay development to empowering drug development and precision clinical diagnostics, our CNV Reference Products are indispensable tools across various facets of cancer research and treatment. Empower Your Research: Explore our diverse range of CNV Reference Products tailored to your specific research needs. From EGFR/MYCN/MET to ERBB2/FGFR3/MYC mixes, we've got you covered with varying copies reflecting the diverse CNV landscape in cancers. Reach out to us today and unlock the potential of our CNV Reference Products! https://lnkd.in/gcbsEhja For Research Use Only. Not for use in diagnostic procedures.
-
Orion Therapeutics, Inc.
While mRNA modification has significantly mitigated inflammation and toxicity in RNA therapies, leading to successful market entries, the same success has not been fully mirrored in lipid-based delivery systems. The toxicity and inflammatory responses associated with these delivery vehicles remain critical hurdles, as evidenced by numerous clinical trial failures involving LNPs and other advanced delivery systems. At Orion Therapeutics, our cutting-edge lipopeptide delivery platform addresses these challenges by enhancing the therapeutic index and reducing toxicity, offering a robust solution for the most challenging hurdles in genetic medicine - The Issue of Delivery. Recognizing the potential of our platform to address a wide range of therapeutic areas, we are actively seeking opportunities to out-license our technology. This strategic approach allows us to collaborate with partners aiming to harness the power of RNA therapies in their own pipelines, expanding the impact of our innovations across the biotech landscape and contributing to the advancement of genetic medicine. Join us at the MassBio Align Summit to explore how our technology is setting new benchmarks; we will be presenting at 10:50 AM tomorrow in the East Tower room. #AlignSummit24 #AlignSummit #AIDrugDiscovery #LNP #RNA
-
Applied BioMath
Are you attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore this week? Check out our poster (#596), "Using a Semi-mechanistic Model to Predict Efficacious Dosing Regimens and Optimal Drug Design Properties for a LNP-delivered mRNA UGT1A1 Replacement Therapy in Crigler-Najjar Syndrome Type 1 Patients," in the Liver Genetic Diseases Poster Session on Wednesday, May 8th! Learn more at: https://lnkd.in/dfEMJWxi #asgct #cellandgenetherapy #genetherapy #mechanisticmodeling #drugdesign #geneticdiseases
-
hubXchange
🔬 Join us at Oligonucleotide Therapeutics Xchange, Boston 2024, on June 21st, for a dynamic roundtable session on "Emerging Opportunities for Liver-Targeting and Extrahepatic Areas" within the Oligonucleotide Discovery track. 🔬 🌟 We're thrilled to announce Lakshmi Bhagat, Associate Scientific Director at Luye Pharma Group, as the facilitator for this insightful discussion. Lakshmi brings a wealth of expertise and leadership from her current role as Associate Director at GeneLeap Biotechnology. 🎓 Lakshmi holds a PhD from the University of Delhi, India, and has honed her skills through postdoctoral training at Massey University, New Zealand, and Harvard Medical School. With over 20 years of experience in the drug development industry, Lakshmi specializes in nucleic acid therapeutics, including innate immune receptor agonists and antagonists, antisense, and siRNA. 💡 Notably, Lakshmi played a pivotal role in the development of Idera Pharmaceuticals's TLR9 agonist, Tilsotolimod, from discovery to Phase 3 clinical trial. Her contributions extend beyond the lab, with co-inventorship of 33 US patents and authorship of 50+ peer-reviewed publications. 🚀 Don't miss the opportunity to gain insights from Lakshmi Bhagat and other industry leaders at Oligonucleotide Therapeutics Xchange 2024. Register now and be part of shaping the future of oligonucleotide therapeutics! 🔒 SECURE YOUR COMPLIMENTARY PASS TODAY! 🔒 https://bit.ly/3wYHLnQ 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 * Agenda subject to change. #OligonucleotideTherapeutics #DrugDiscovery #Biotech #Pharma #Innovation #DrugDevelopment #Science #Research #Oligonucleotides #Therapeutics #Healthcare #LifeSciences #Leadership #Roundtable #BostonEvents #Networking #ScientificCommunity #ClinicalTrials #MedicalResearch #Genetics #hubXchange #FreePass #RegisterNow #ComplimentaryPass
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Patrick Savickas
2 others named Patrick Savickas are on LinkedIn
See others named Patrick Savickas